Hizentra flexibility to suit individual patient lifestyles**

- Approved flexible administration daily to once every two weeks
- With no upper limit, you can now determine an infusion rate based on individual patient tolerability**
- The only SCig licensed for CIDP
- The only SCig licensed for storage at room temperature for 30 months1
- Proven to protect PID patients from serious bacterial infections

Flexible administration for individualised therapy

Dosage and method of administration:
Individuals: The initial subcutaneous dose is 0.2 to 0.4 g/kg body weight per week. The subcutaneous dose is 0.2 to 0.4 g/kg body weight per week. The dose may need to be individualised dependent on the pharmacokinetics (see section 5.2 of SmPC), clinical response and IgG trough levels. A loading dose of at least 0.2-0.5g/kg (1-2.5ml/kg) bodyweight – divided into section 5.1. Hizentra has not been evaluated in clinical studies demonstrating need for continued therapy. Direct comparative measures to prevent infections resulting from the use of medicinal products to transmit infective agents cannot be totally excluded. The product is essentially sodium free.

Immunomodulatory therapy in CIDP patients aged over 18 years. The dose may need to be individualised dependent on the pharmacokinetics (see section 5.2 of SmPC), clinical response and IgG trough levels. A loading dose of at least 0.2-0.5g/kg (1-2.5ml/kg) bodyweight – divided into


** Maximum infusion rate may be determined by pump type, if used.

The only SCIg licensed for storage at room temperature for 30 months1

For a copy of the SmPC or further medical information, please visit our website www.hizentra.com, or contact your local representative.

References:

Updated dosing information inside1

Hizentra® (Human Normal Immunoglobulin (SCIg) 200mg/ml for subcutaneous injection)

** The only SCIg licensed for storage at room temperature for 30 months1

** The only SCIg licensed for storage at room temperature for 30 months1
Flexible administration of Hizentra provides comparable serum IgG levels

Consider the freedom of Hizentra

- Training time up to 2.5 hours
- No cost for pumps, batteries or maintenance
- Planned holidays can be accommodated, missed doses replaced

Pharmacokinetic simulations comparing the steady-state concentration-time profiles of plasma IgG following daily, weekly, and every 2 weeks subcutaneous immunoglobulin (SCIG) administration with Hizentra® in an adult cyclosporine regimen.

Adapted from Safety and Efficacy based on pharmacokinetic modeling and simulations.

Hizentra®

Human Normal Immunoglobulin (IGG)
200 mg/mL solution for subcutaneous injection

* Subcutaneous "Press and push" injection